[go: up one dir, main page]

DK3585891T3 - Fremgangsmåder til oprensning af messenger-rna - Google Patents

Fremgangsmåder til oprensning af messenger-rna Download PDF

Info

Publication number
DK3585891T3
DK3585891T3 DK18711201.6T DK18711201T DK3585891T3 DK 3585891 T3 DK3585891 T3 DK 3585891T3 DK 18711201 T DK18711201 T DK 18711201T DK 3585891 T3 DK3585891 T3 DK 3585891T3
Authority
DK
Denmark
Prior art keywords
purification
methods
messenger rna
messenger
rna
Prior art date
Application number
DK18711201.6T
Other languages
English (en)
Inventor
Jonathan Abysalh
Daniel Crawford
Frank Derosa
Shrirang Karve
Anusha Dias
Michael Heartlein
Original Assignee
Translate Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translate Bio Inc filed Critical Translate Bio Inc
Application granted granted Critical
Publication of DK3585891T3 publication Critical patent/DK3585891T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1017Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502753Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/02Adapting objects or devices to another
    • B01L2200/028Modular arrangements
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/16Reagents, handling or storing thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/06Auxiliary integrated devices, integrated components
    • B01L2300/0681Filter
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0403Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0409Moving fluids with specific forces or mechanical means specific forces centrifugal forces
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2523/00Reactions characterised by treatment of reaction samples
    • C12Q2523/10Characterised by chemical treatment
    • C12Q2523/113Denaturating agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2523/00Reactions characterised by treatment of reaction samples
    • C12Q2523/30Characterised by physical treatment
    • C12Q2523/308Adsorption or desorption
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y201/00Transferases transferring one-carbon groups (2.1)
    • C12Y201/03Carboxy- and carbamoyltransferases (2.1.3)
    • C12Y201/03003Ornithine carbamoyltransferase (2.1.3.3)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Clinical Laboratory Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK18711201.6T 2017-02-27 2018-02-27 Fremgangsmåder til oprensning af messenger-rna DK3585891T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762463998P 2017-02-27 2017-02-27
PCT/US2018/019954 WO2018157133A1 (en) 2017-02-27 2018-02-27 Methods for purification of messenger rna

Publications (1)

Publication Number Publication Date
DK3585891T3 true DK3585891T3 (da) 2021-11-22

Family

ID=61628474

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18711201.6T DK3585891T3 (da) 2017-02-27 2018-02-27 Fremgangsmåder til oprensning af messenger-rna

Country Status (11)

Country Link
US (2) US10808241B2 (da)
EP (2) EP3971291A1 (da)
AU (1) AU2018224843B2 (da)
CA (1) CA3054321A1 (da)
CY (1) CY1124735T1 (da)
DK (1) DK3585891T3 (da)
ES (1) ES2899323T3 (da)
HU (1) HUE059025T2 (da)
IL (1) IL268857B2 (da)
MA (1) MA47605A (da)
WO (1) WO2018157133A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
ES2981185T3 (es) 2013-03-14 2024-10-07 Translate Bio Inc Métodos para la purificación de ARN mensajero
HUE059025T2 (hu) * 2017-02-27 2022-10-28 Translate Bio Inc Módszerek a hírvívõ RNS tisztítására
WO2019104152A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
JP7448488B2 (ja) * 2018-05-15 2024-03-12 トランスレイト バイオ, インコーポレイテッド メッセンジャーrnaの皮下送達
WO2020041793A1 (en) * 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
EP3877538A1 (en) * 2018-11-08 2021-09-15 Translate Bio, Inc. Methods and compositions for messenger rna purification
PT3924487T (pt) 2019-02-11 2024-05-31 Ethris Gmbh Purificação de arnm por filtração de fluxo tangencial
KR20220029556A (ko) * 2019-05-15 2022-03-08 트랜슬레이트 바이오 인코포레이티드 전령 rna의 정제 방법
CN115461042A (zh) 2019-12-20 2022-12-09 翻译生物公司 制备负载mrna的脂质纳米颗粒的改进方法
WO2021127394A2 (en) 2019-12-20 2021-06-24 Translate Bio, Inc. Rectal delivery of messenger rna
WO2021163134A1 (en) 2020-02-10 2021-08-19 Translate Bio, Inc. Methods and compositions for messenger rna purification
WO2021173840A1 (en) 2020-02-25 2021-09-02 Translate Bio, Inc. Improved processes of preparing mrna-loaded lipid nanoparticles
EP4146680A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
AU2021269042A1 (en) 2020-05-07 2023-02-02 Translate Bio, Inc. Optimized nucleotide sequences encoding SARS-CoV-2 antigens
AU2021273502A1 (en) 2020-05-15 2023-02-02 Translate Bio, Inc. Lipid nanoparticle formulations for mRNA delivery
JP2023544167A (ja) * 2020-10-01 2023-10-20 トランスレイト バイオ, インコーポレイテッド メッセンジャーrnaの精製のための方法
JP2023544197A (ja) 2020-10-06 2023-10-20 トランスレイト バイオ, インコーポレイテッド 脂質ナノ粒子の改善された方法および製剤
WO2022081548A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing ice-based lipid nanoparticles
AU2021361986A1 (en) 2020-10-12 2023-06-15 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
US20220218622A1 (en) 2020-10-14 2022-07-14 George Mason Research Foundation, Inc. Ionizable lipids and methods of manufacture and use thereof
US20250268994A1 (en) 2021-03-25 2025-08-28 Translate Bio, Inc. Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
WO2022225918A1 (en) 2021-04-19 2022-10-27 Translate Bio, Inc. Improved compositions for delivery of mrna
JP2024527541A (ja) 2021-07-01 2024-07-25 トランスレイト バイオ, インコーポレイテッド Mrnaの送達のための組成物
CN118591398A (zh) 2021-11-10 2024-09-03 翻译生物公司 用于治疗原发性纤毛运动不良症的组合物和方法
CA3263324A1 (en) 2022-07-29 2024-02-01 Sanofi Pasteur Inc ETHANOL-FREE MRNA PURIFICATION PROCESSES
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
CN120265279A (zh) 2022-11-21 2025-07-04 翻译生物公司 信使rna的干粉配制品的组合物及其使用方法
AU2023394992A1 (en) 2022-12-15 2025-07-31 Sanofi Pasteur Inc. Mrna encoding influenza virus-like particle
CN120475991A (zh) 2022-12-20 2025-08-12 赛诺菲巴斯德有限公司 鼻病毒mRNA疫苗
EP4638772A2 (en) 2022-12-23 2025-10-29 Sanofi Pasteur Inc. Optimized tailing of messenger rna
CN120858173A (zh) 2023-03-07 2025-10-28 赛诺菲巴斯德有限公司 用kp34聚合酶制造信使rna
WO2024194767A1 (en) 2023-03-17 2024-09-26 BioNTech SE Automated drug production system
CN120957707A (zh) 2023-04-17 2025-11-14 赛诺菲巴斯德有限公司 可复溶干粉配制品及其使用方法
WO2025017151A1 (en) 2023-07-18 2025-01-23 Sanofi Stable poly(a)-encoding messenger rna templates
WO2025104351A1 (en) 2023-11-17 2025-05-22 Sanofi Pasteur Inc. Hplc-based assays for detecting multiple mrna constructs
WO2025141200A1 (en) 2023-12-29 2025-07-03 Sanofi Pasteur Inc. Modified rna polymerases

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5139667A (en) 1988-12-20 1992-08-18 Sparkler Filters, Inc. Nutsche process filter drive unit
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5234809A (en) * 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
US5544425A (en) 1995-05-17 1996-08-13 Mallinckrodt Medical, Inc. Aggressive convective drying in a nutsche type filter/dryer
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
JP3930616B2 (ja) 1997-08-25 2007-06-13 住友化学株式会社 2−アミノ−6置換プリンの精製方法
DE19917558C2 (de) 1999-04-19 2003-05-08 Joachim Schwindling Filtrationsapparat
US7157603B2 (en) 2001-05-14 2007-01-02 Polytag Technology Sa Method for the separation of oligomeric N-substituted (meth)acrylamide compounds and conjugates thereof which are reversibly thermally precipitating
DE10131107A1 (de) 2001-06-27 2003-01-09 Mann & Hummel Filter Filtervorrichtung bzw. schwenkbares Filtermedium für diese Filtervorrichtung
JP2004167345A (ja) 2002-11-19 2004-06-17 Sumitomo Chem Co Ltd 固体粒子の洗浄方法
US7267950B2 (en) 2003-05-01 2007-09-11 Veridex, Lcc Rapid extraction of RNA from cells and tissues
US7709240B2 (en) 2004-04-28 2010-05-04 Amano Enzyme Inc. AMP deaminase originating streptomyces and utilization thereof
US7473511B2 (en) * 2004-12-15 2009-01-06 Fuji Xerox Co., Ltd. Particle dispersion for electrostatic image-developing toners, electrostatic image-developing toner, and method for producing the same
US7494794B2 (en) 2006-03-31 2009-02-24 Toyo Boseki Kabushiki Kaisha Glucose dehydrogenase
WO2008078646A1 (ja) 2006-12-22 2008-07-03 Ajinomoto Co., Inc. アミノ酸又は核酸の結晶の分離方法
US20090065435A1 (en) 2007-09-10 2009-03-12 Powell Intellectual Property Holdings, Llc Modified Biogenic Silica and Method for Purifying a Liquid
US20090148384A1 (en) 2007-12-10 2009-06-11 Fischer Katrin Functionalized, solid polymer nanoparticles comprising epothilones
CN102065870B (zh) 2008-04-16 2014-11-19 比奥根艾迪克Ma公司 使用聚亚烷基二醇和过渡金属分离生物大分子的方法
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
US20130059008A1 (en) * 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
WO2011031566A1 (en) 2009-08-27 2011-03-17 Newlight Technologies, Llc Process for the production of polyhydroxyalkanoates
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
EP3403647A1 (en) 2009-12-01 2018-11-21 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
WO2013016446A2 (en) * 2011-07-25 2013-01-31 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
ES2762873T3 (es) 2012-03-29 2020-05-26 Translate Bio Inc Lípidos catiónicos ionizables
EP2830596B1 (en) 2012-03-29 2020-12-30 Translate Bio, Inc. Lipid-derived neutral nanoparticles
MX2014015041A (es) 2012-06-08 2015-06-17 Shire Human Genetic Therapies Administración pulmonar de arnm a células objetivo no pulmonares.
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
WO2014152659A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger rna
MX2015011945A (es) 2013-03-14 2015-12-01 Shire Human Genetic Therapies Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
EP3431592A1 (en) 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
CA2904151C (en) 2013-03-14 2023-09-12 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
ES2981185T3 (es) 2013-03-14 2024-10-07 Translate Bio Inc Métodos para la purificación de ARN mensajero
LT2970456T (lt) 2013-03-14 2021-08-10 Translate Bio, Inc. Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui
US10266559B2 (en) 2013-03-14 2019-04-23 Translate Bio, Inc. Ribonucleic acids with 4′-thio-modified nucleotides and related methods
HUE042072T2 (hu) * 2013-03-15 2019-06-28 Glaxosmithkline Biologicals Sa Eljárások RNS tisztítására
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
MX2016005238A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
US20150110857A1 (en) 2013-10-22 2015-04-23 Shire Human Genetic Therapies, Inc. Cns delivery of mrna and uses thereof
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
RS58337B1 (sr) 2014-03-24 2019-03-29 Translate Bio Inc Irnk terapija za lečenje očnih oboljenja
MX373952B (es) 2014-04-25 2020-07-13 Shire Human Genetic Therapies Métodos de purificación de arn mensajero.
CN106659731A (zh) 2014-05-30 2017-05-10 夏尔人类遗传性治疗公司 用于递送核酸的可生物降解脂质
UA121863C2 (uk) 2014-06-24 2020-08-10 Транслейт Байо, Інк. Стереохімічно збагачені композиції для доставки нуклеїнових кислот
EP3164112A1 (en) 2014-07-02 2017-05-10 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
CA2979695C (en) 2015-03-19 2025-02-06 Translate Bio Inc RNA THERAPY FOR POMPE DISEASE
KR101693166B1 (ko) 2016-07-12 2017-01-06 정수영 분말 액체 혼합물용 누체 여과 건조 장치
HUE059025T2 (hu) * 2017-02-27 2022-10-28 Translate Bio Inc Módszerek a hírvívõ RNS tisztítására
BR112020021037A2 (pt) 2018-04-25 2021-01-19 Ethris Gmbh Composição, composição sólida, processo para a preparação de uma composição, método para preservar uma formulação de nano ou micropartícula de um agente terapeuticamente ativo, uso de um composto selecionado de alcanos c3-c5 substituídos com um ou dois grupos hidróxi, e, dispositivo

Also Published As

Publication number Publication date
IL268857B2 (en) 2024-09-01
CA3054321A1 (en) 2018-08-30
EP3585891A1 (en) 2020-01-01
CY1124735T1 (el) 2022-07-22
US20180251755A1 (en) 2018-09-06
IL268857A (en) 2019-10-31
WO2018157133A1 (en) 2018-08-30
EP3585891B1 (en) 2021-10-27
US10808241B2 (en) 2020-10-20
MA47605A (fr) 2020-01-01
EP3971291A1 (en) 2022-03-23
US20210123041A1 (en) 2021-04-29
ES2899323T3 (es) 2022-03-10
HUE059025T2 (hu) 2022-10-28
AU2018224843A1 (en) 2019-09-19
US11976272B2 (en) 2024-05-07
AU2018224843B2 (en) 2024-08-15
IL268857B1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
DK3585892T3 (da) Fremgangsmåder til oprensning af messenger-rna
DK3585891T3 (da) Fremgangsmåder til oprensning af messenger-rna
DK3636742T3 (da) Fremgangsmåder til oprensning af messenger-rna
DK3585886T5 (da) Storskalasyntese af messenger-rna
DK4140491T5 (da) Fremgangsmåde til syntetisering af RNA'er med 5'-kappe
DK3467108T3 (da) Fremgangsmåder til oprensning af messenger-RNA
IL263690A (en) Purification of multispecific antibodies
DK3445850T3 (da) Fremgangsmåder til tilvejebringelse af enkeltstrenget rna
DK3268390T3 (da) Fremgangsmåder til oprensning af bispecifikke antistoffer
DK3377059T3 (da) Hæmmere af cxcr2
DK3292134T3 (da) Metode til dyrkning af akkermansia
DK3337902T3 (da) 3'-utr-sekvenser til stabilisering af rna
EP3349649A4 (en) NAVIGATION OF TUBULAR NETWORKS
DK3294885T3 (da) Fremgangsmåde til at fremstille rna
DK3463483T3 (da) Behandling af primær ciliedyskinesi med syntetisk messenger-RNA
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
DK3113858T3 (da) Fremgangsmåde til oprensning af il-15/il-15ralpha-baserede konjugater
DK3510042T3 (da) Fremgangsmåde til rensning af antistoffer
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
DK3607068T3 (da) RNA-interferensmedieret inhibering af TMPRSS6
DK3665173T3 (da) Ny fremgangsmåde til yntetisering af amanitiner
DK3680000T3 (da) Fremgangsmåder til oprensning af antistoffer
DK3356386T3 (da) Fremgangsmåde til behandling af melanocortin-4 receptorbane-associerede lidelser
DK3347481T3 (da) Fremgangsmåde til oprensning af biomassehydrolysat
DK3307878T3 (da) Fremgangsmåder til fremstilling og oprensning af nukleinsyreholdige sammensætninger